Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Price Target from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $29.50.

A number of research analysts recently commented on the company. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. Morgan Stanley decreased their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. HC Wainwright cut their price target on shares of Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Finally, Bank of America decreased their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.30% of the stock is owned by corporate insiders.

Institutional Trading of Arcus Biosciences

A number of hedge funds have recently made changes to their positions in the company. R Squared Ltd acquired a new position in shares of Arcus Biosciences in the fourth quarter valued at approximately $26,000. Point72 Hong Kong Ltd acquired a new position in Arcus Biosciences in the 3rd quarter valued at approximately $47,000. Lazard Asset Management LLC increased its position in Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the period. US Bancorp DE raised its stake in shares of Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after acquiring an additional 6,615 shares during the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after purchasing an additional 9,408 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $10.16 on Tuesday. The firm has a market cap of $1.07 billion, a PE ratio of -3.23 and a beta of 0.84. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The stock’s fifty day moving average price is $13.79 and its two-hundred day moving average price is $15.54. Arcus Biosciences has a one year low of $10.12 and a one year high of $20.31.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.